{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:08:51Z","timestamp":1764688131160,"version":"3.41.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda UK Ltd.","award":["Takeda UK Ltd."],"award-info":[{"award-number":["Takeda UK Ltd."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Vedolizumab is a gut-selective, anti\u2013lymphocyte trafficking biologic therapy for inflammatory bowel disease (IBD). Clinical trials have demonstrated the positive impact of vedolizumab on patient quality of life (QoL); however, real-world evidence of its impact is limited. We evaluated vedolizumab impact on QoL of patients with IBD during the first 52 weeks of treatment in real-world practice in the United Kingdom and Ireland.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this prospective observational study, patients with IBD initiated on vedolizumab completed 4 validated IBD-specific QoL questionnaires at baseline and weeks 14, 26, and 52. The primary endpoint was change in mean Short Inflammatory Bowel Disease Questionnaire (SIBDQ) score. Secondary endpoints included changes in mean scores and sub-scores for other QoL questionnaires.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Overall, 61 patients were enrolled, including 22 with Crohn\u2019s disease (CD) and 39 with ulcerative colitis (UC). At week 52, the mean change in SIBDQ scores from baseline was statistically significant (+\u200912.3 [<jats:italic>p<\/jats:italic>\u2009=\u20090.0123] for CD and +\u200910.8 [<jats:italic>p<\/jats:italic>\u2009=\u20090.0037] for UC) and clinically meaningful (considered as a\u2009\u2265\u200910-point change). A significant improvement in mean SIBDQ scores was seen as early as week 14 for both CD and UC cohorts (<jats:italic>p<\/jats:italic>\u2009=\u20090.0256 and <jats:italic>p<\/jats:italic>\u2009=\u20090.0348, respectively).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These real-world findings, using multiple validated tools, demonstrate that vedolizumab treatment for IBD is associated with measurable improvements in QoL from baseline.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41687-025-00846-9","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:48:37Z","timestamp":1751381317000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Health-related quality of life outcomes among vedolizumab-treated patients with inflammatory bowel disease in the UK and Ireland: a 52-week observational study (OCTAVO)"],"prefix":"10.1186","volume":"9","author":[{"given":"Gareth","family":"Parkes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayesha","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Beales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Creed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Said","family":"Din","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolas","family":"Plevris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niamh","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Heggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Meadowcroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Wallington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aileen","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"846_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/jcm5120118","volume":"5","author":"O W\u00e9ra","year":"2016","unstructured":"W\u00e9ra O, Lancellotti P, Oury C (2016) The dual role of neutrophils in inflammatory bowel diseases. J Clin Med 5:118","journal-title":"J Clin Med"},{"key":"846_CR2","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/MEG.0000000000000685","volume":"28","author":"AGEM De Boer","year":"2016","unstructured":"De Boer AGEM, Bennebroek Evertsz\u2019 F, Stokkers PC, Bockting CL, Sanderman R, Hommes DW et al (2016) Employment status, difficulties at work and quality of life in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 28:1130\u20131136","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"846_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.crohns.2007.06.005","volume":"1","author":"S Ghosh","year":"2007","unstructured":"Ghosh S, Mitchell R (2007) Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn\u2019s and Ulcerative Colitis associations (EFCCA) patient survey. J Crohns Colitis 1:10\u201320","journal-title":"J Crohns Colitis"},{"key":"846_CR4","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/ibd.20511","volume":"14","author":"LM Lix","year":"2008","unstructured":"Lix LM, Graff LA, Walker JR, Clara I, Rawsthorne P, Rogala L et al (2008) Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis 14:1575\u20131584","journal-title":"Inflamm Bowel Dis"},{"key":"846_CR5","first-page":"1571","volume":"91","author":"EJ Irvine","year":"1996","unstructured":"Irvine EJ, Zhou Q, Thompson AK (1996) The short inflammatory bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT investigators. Canadian Crohn\u2019s Relapse Prevention Trial. Am J Gastroenterol 91:1571\u20131578","journal-title":"Am J Gastroenterol"},{"key":"846_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/00006842-199111000-00010","volume":"53","author":"DA Drossman","year":"1991","unstructured":"Drossman DA, Leserman J, Li ZM, Mitchell CM, Zagami EA, Patrick DL (1991) The rating form of IBD patient concerns: a new measure of health status. Psychosom Med 53:701\u2013712","journal-title":"Psychosom Med"},{"key":"846_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0002-9270(01)04037-0","volume":"97","author":"M Simr\u00e9n","year":"2002","unstructured":"Simr\u00e9n M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Bj\u00f6rnsson ES (2002) Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 97:389\u2013396","journal-title":"Am J Gastroenterol"},{"key":"846_CR8","unstructured":"IBD UK IBD Standards. https:\/\/ibduk.org\/ibd-standards. Accessed 19 Sep 2022"},{"issue":"1","key":"846_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V et al (2022) ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis 16(1):2\u201317","journal-title":"J Crohns Colitis"},{"issue":"1","key":"846_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T et al (2020) ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis 14(1):4\u201322","journal-title":"J Crohns Colitis"},{"key":"846_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1177\/2040622315586970","volume":"6","author":"LN Cherry","year":"2015","unstructured":"Cherry LN, Yunker NS, Lambert ER, Vaughan D, Lowe DK (2015) Vedolizumab: an \u03b14\u03b27 integrin antagonist for ulcerative colitis and Crohn\u2019s disease. Ther Adv Chronic Dis 6:224\u2013233","journal-title":"Ther Adv Chronic Dis"},{"key":"846_CR12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE et al (2013) Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med 369:711\u2013721","journal-title":"N Engl J Med"},{"key":"846_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ et al (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369:699\u2013710","journal-title":"N Engl J Med"},{"key":"846_CR14","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, T\u00f6r\u00fcner M et al (2019) Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med 381:1215\u20131226","journal-title":"N Engl J Med"},{"key":"846_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/apt.13852","volume":"45","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, Patel H, Colombel JF, Rubin DT, James A, Mody R et al (2017) Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Aliment Pharmacol Ther 45:264\u2013275","journal-title":"Aliment Pharmacol Ther"},{"key":"846_CR16","first-page":"412","volume":"11","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, Loftus EV Jr, Colombel JF, Feagan BG, Sandborn WJ, Sands BE et al (2017) Long-term efficacy of vedolizumab for Crohn\u2019s disease. J Crohns Colitis 11:412\u2013424","journal-title":"J Crohns Colitis"},{"key":"846_CR17","unstructured":"First Line Research http:\/\/www.firstlineresearch.com. Accessed 16 Sep 2022"},{"key":"846_CR18","unstructured":"Confirmit https:\/\/www.confirmit.com. Accessed Sep 16 2022"},{"key":"846_CR19","unstructured":"Confirmit - secure servers https:\/\/extranet.confirmit.com\/library\/security. Accessed 16 Sep 2022"},{"key":"846_CR20","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1136\/gutjnl-2013-305600","volume":"63","author":"K Bodger","year":"2014","unstructured":"Bodger K, Ormerod C, Shackcloth D, Harrison M, IBD Control Collaborative (2014) Development and validation of a rapid, generic measure of disease control from the patient\u2019s perspective: the IBD-Control questionnaire. Gut 63:1092\u20131102","journal-title":"Gut"},{"key":"846_CR21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.clinthera.2008.02.016","volume":"30","author":"MC Reilly","year":"2008","unstructured":"Reilly MC, Gerlier L, Brabant Y, Brown M (2008) Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn\u2019s disease. Clin Ther 30:393\u2013404","journal-title":"Clin Ther"},{"key":"846_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 4:353\u2013365","journal-title":"PharmacoEconomics"},{"key":"846_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s41687-018-0088-8","volume":"2","author":"A Yarlas","year":"2018","unstructured":"Yarlas A, Maher SM, Bayliss MS, Lovley A, Cappelleri JC, DiBonaventura MD (2018) Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review. J Patient Rep Outcomes 2:62","journal-title":"J Patient Rep Outcomes"},{"key":"846_CR24","unstructured":"Reilly Associates. WPAI scoring. http:\/\/www.reillyassociates.net\/WPAI_Scoring.html. Accessed 19 Sep 2022"},{"key":"846_CR25","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.cgh.2017.10.019","volume":"16","author":"MJ de Jong","year":"2018","unstructured":"de Jong MJ, Huibregtse R, Masclee AAM, Jonkers DMAE, Pierik MJ (2018) Patient-reported outcome measures for use in clinical trials and clinical practice in inflammatory bowel diseases: a systematic review. Clin Gastroenterol Hepatol 16:648\u2013663e643","journal-title":"Clin Gastroenterol Hepatol"},{"key":"846_CR26","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, D\u2019Amico F, Dhaliwal J, Griffiths AM et al (2021) STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160:1570\u20131583","journal-title":"Gastroenterology"},{"key":"846_CR27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/13696998.2020.1801187","volume":"23","author":"E Walter","year":"2020","unstructured":"Walter E, Hausberger SC, Gro\u00df E, Siebert U (2020) Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria. J Med Econ 23:1061\u20131071","journal-title":"J Med Econ"},{"key":"846_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12876-020-1164-0","volume":"20","author":"A Armuzzi","year":"2020","unstructured":"Armuzzi A, Tarallo M, Lucas J, Bluff D, Hoskin B, Bargo D et al (2020) The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. BMC Gastroenterol 20:18","journal-title":"BMC Gastroenterol"},{"key":"846_CR29","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1007\/s10620-020-06647-y","volume":"66","author":"S van Gennep","year":"2021","unstructured":"van Gennep S, de Boer NKH, Gielen ME, Rietdijk ST, Gecse KB, Ponsioen CY et al (2021) Impaired quality of working life in inflammatory bowel disease patients. Dig Dis Sci 66:2916\u20132924","journal-title":"Dig Dis Sci"},{"key":"846_CR30","first-page":"52","volume":"26","author":"N Viazis","year":"2013","unstructured":"Viazis N, Mantzaris G, Karmiris K et al (2013) Inflammatory bowel disease: Greek patients perspective on quality of life, information on the disease, work productivity and family support. Ann Gastroenterol 26:52\u201358","journal-title":"Ann Gastroenterol"},{"key":"846_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10198-014-0603-7","volume":"15","author":"MD Michael","year":"2014","unstructured":"Michael MD, B\u00e1lint A, Lov\u00e1sz BD et al (2014) Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ 15:121\u2013128","journal-title":"Eur J Health Econ"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00846-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-025-00846-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00846-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:48:46Z","timestamp":1751381326000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-025-00846-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["846"],"URL":"https:\/\/doi.org\/10.1186\/s41687-025-00846-9","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"8 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (Revision 5). Oral informed consent was obtained from all patients for being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GP declares honoraria from AbbVie, Ferring, Galapagos, Janssen, Takeda, and Tillotts; travel grants or fellowship from AbbVie, Janssen, Takeda, and Tillotts; and is the Director and shareholder in Ampersand Health. NP declares consultancy fees from Takeda and speaker and travel support from AbbVie, Takeda, Norgine, and Janssen. AF declares speaker fees from AbbVie, Actavis, Allergan, Dr Falk Pharma, Ferring, Janssen, Pharmacosmos, Shield, Takeda, and Tillotts. TC is on advisory boards for Takeda. AA is on advisory boards for and declares speaker fees from Takeda, Otsuka, Janssen, and Dr Falk and speaker fees from Kyowa Kirin, AbbVie, Biogen, and Almirall. SM is an employee of Takeda and holds stock in Takeda. Nho was an employee of Takeda at the time the study was conducted. NHe is a contractor for Takeda UK. Nho and NHe do not hold any Takeda stock or stock options. MW was an employee of OPEN VIE when the study was conducted. IB, MB, and SD declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}